

Jan Delaware  
Access DB# 120310

**SEARCH REQUEST FORM**

Scientific and Technical Information Center

Requester's Full Name: Sabrina Gray Examiner #: 74141 Date: 4/23/04  
 Art Unit: 1616 Phone Number: (404) 206-2222 Serial Number: 10/007451  
 Mail Box and Bldg Room Locations: 4C70 Rm. 4A45 Results Format Preferred (circle): PAPER  DISK  E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.


Title of Invention: Modified hydroxyl-substituted aromatic polyesters having a protective coating

Inventors (please provide full names): Douglas F. Covey, Charles J. Schatzky

Earliest Priority Filing Date: 11/3/2000

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search for compds of Cls 1



Please see attached sheet

Thank you!

<b>STAFF USE ONLY</b>		Type of Search	Vendors and cost where applicable
Searcher: <u>Jan</u>		NA Sequence (#) <input type="checkbox"/>	STN <input checked="" type="checkbox"/>
Searcher Phone #:	<u>22504</u>	AA Sequence (#) <input type="checkbox"/>	Dialog _____
Searcher Location:		Structure (#) <input checked="" type="checkbox"/>	Questel/Oribit _____
Date Searcher Picked Up:	<u>4/24</u>	Bibliographic <input type="checkbox"/>	Dr. Link _____
Inv. Completed:	<u>4/24</u>	Ligation <input type="checkbox"/>	Lexis/Nexis _____
Searcher Prep & Review Time:	<u>15</u>	Fulltext <input type="checkbox"/>	Sequence Systems _____
Clerical Prep Time:	<u>15</u>	Patent Family <input type="checkbox"/>	WWW/Internet _____
Online Time:	<u>150</u>	Other <input type="checkbox"/>	Other (specify) _____

=> fil reg  
FILE 'REGISTRY' ENTERED AT 13:00:07 ON 24 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 APR 2004 HIGHEST RN 676578-75-9  
DICTIONARY FILE UPDATES: 23 APR 2004 HIGHEST RN 676578-75-9


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que 130  
L8 83954 SEA FILE=REGISTRY ABB=ON PLU=ON C5-C6-C6-C6/ES AND NR>=5  
L9 STR



#### NODE ATTRIBUTES:


DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

#### GRAPH ATTRIBUTES:

RSPEC 1  
NUMBER OF NODES IS 17

#### STEREO ATTRIBUTES: NONE

L11 78379 SEA FILE=REGISTRY SUB=L8 SSS FUL L9  
L12 STR



VAR G1=C/18  
 VAR G2=C/18/20/22

## NODE ATTRIBUTES:


CONNECT IS M1 RC AT 1  
 CONNECT IS M1 RC AT 2  
 CONNECT IS M1 RC AT 3  
 CONNECT IS M1 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RSPEC 1  
 NUMBER OF NODES IS 23

## STEREO ATTRIBUTES: NONE

L14 1600 SEA FILE=REGISTRY SUB=L11 CSS FUL L12  
 L22 STR



VAR G1=OH/CY/H/AK

## NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RSPEC 1  
 NUMBER OF NODES IS 21

## STEREO ATTRIBUTES: NONE

L23 SCR 1700  
 L25 323 SEA FILE=REGISTRY SUB=L14 SSS FUL L22 AND L23  
 L26 150 SEA FILE=REGISTRY ABB=ON PLU=ON L25 AND (IDS OR MXS OR PMS  
 OR CCS OR AYS OR MNS)/CI  
 L27 173 SEA FILE=REGISTRY ABB=ON PLU=ON L25 NOT L26  
 L28 57 SEA FILE=REGISTRY ABB=ON PLU=ON L27 AND NC>=2  
 L29 116 SEA FILE=REGISTRY ABB=ON PLU=ON L27 NOT L28  
 L30 13 SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND 638/RID

=> d his

(FILE 'HOME' ENTERED AT 12:38:42 ON 24 APR 2004)  
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 12:38:59 ON 24 APR 2004

L1 1 S US20020103178/PN OR (WO2001-US46924 OR US2000-245791#)/AP, PRN  
 E COVEY D/AU  
 L2 199 S E7,E11,E12  
 SEL RN L1

## FILE 'REGISTRY' ENTERED AT 12:40:09 ON 24 APR 2004

L3           31 S E1-E31  
 L4           11 S L3 AND NR>=5  
 L5           STR  
 L6           SCR 1842  
 L7           50 S L5 AND L6  
             E C5-C6-C6-ES  
 L8           83954 S E3 AND NR>=5  
 L9           STR L5  
 L10          50 S L9 SAM SUB=L8  
 L11          78379 S L9 FUL SUB=L8  
 L12          STR L5  
 L13          50 S L12 CSS SAM SUB=L11  
 L14          1600 S L12 CSS FUL SUB=L11  
             SAV L14 QAZI007/A  
 L15          STR L12  
 L16          0 S L15 CSS SAM SUB=L14  
 L17          50 S L15 SAM SUB=L14  
 L18          STR L12  
 L19          0 S L18 SAM SUB=L14  
 L20          STR L18  
 L21          0 S L20 SAM SUB=L14  
 L22          STR L5  
 L23          SCR 1700  
 L24          14 S L22 AND L23 SAM SUB=L14  
 L25          323 S L22 AND L23 FUL SUB=L14  
             SAV L25 QAZI007A/A  
 L26          150 S L25 AND (IDS OR MXS OR PMS OR CCS OR AYS OR MNS)/CI  
 L27          173 S L25 NOT L26  
 L28          57 S L27 AND NC>=2  
 L29          116 S L27 NOT L28  
 L30          13 S L29 AND 638/RID  
 L31          103 S L29 NOT L30  
 L32          57 S L31 AND NR>=6  
 L33          46 S L31 NOT L32  
 L34          13 S L4,L30  
             SAV L30 QAZI007B/A

## FILE 'HCAOLD' ENTERED AT 12:59:37 ON 24 APR 2004

L35          0 S L34

## FILE 'HCAPLUS' ENTERED AT 12:59:39 ON 24 APR 2004.

L36          5 S L34  
 L37          3 S L36 AND L1,L2  
 L38          5 S L36,L37

## FILE 'USPATFULL, USPAT2' ENTERED AT 12:59:57 ON 24 APR 2004


L39          2 S L34

## FILE 'REGISTRY' ENTERED AT 13:00:07 ON 24 APR 2004

=> d ide can tot l34

L34 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 535921-41-6 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
       (9β,14β,17β)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C28 H38 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:987

L34 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 444571-93-1 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
(17 $\beta$ ) - (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C28 H38 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:135223

L34 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 422566-94-7 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
(8 $\alpha$ ,9 $\beta$ ,13 $\alpha$ ,14 $\beta$ ,17 $\alpha$ ) - (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN ZYC 33  
FS STEREOSEARCH  
MF C28 H38 O2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 422509-02-2 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl-, (17 $\beta$ )- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN ZYC 26  
FS STEREOSEARCH  
MF C32 H46 O2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 422509-01-1 REGISTRY  
CN Estra-1,3,5(10)-triene-3,17-diol, 4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-, (17 $\beta$ )- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH

MF C29 H40 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 422509-00-0 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8α,9β,13α,14β)- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN ZYC 22  
 FS STEREOSEARCH  
 MF C29 H38 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 422508-99-4 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-tricyclo[3.3.1.13,7]dec-1-yl-,  
 (8 $\alpha$ ,9 $\beta$ ,13 $\alpha$ ,14 $\beta$ )- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C28 H36 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 422508-97-2 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-  
 tricyclo[3.3.1.13,7]dec-1-yl-, (17 $\alpha$ )- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C32 H46 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 422508-96-1 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
 (17 $\alpha$ )- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C28 H38 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 422508-95-0 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8 $\alpha$ ,9 $\beta$ ,13 $\alpha$ ,14 $\beta$ ,17.alp ha.)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C32 H46 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 422508-94-9 REGISTRY  
 CN Estra-1,3,5(10)-triene-3,17-diol, 4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8 $\alpha$ ,9 $\beta$ ,13 $\alpha$ ,14 $\beta$ ,17 $\alpha$ )- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C29 H40 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 422508-93-8 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C32 H44 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369889

L34 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 21003-01-0 REGISTRY  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(tricyclo[3.3.1.13,7]dec-1-yl)-  
 (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Estra-1,3,5(10)-trien-17-one, 2-(1-adamantyl)-3-hydroxy- (8CI)  
 OTHER NAMES:  
 CN ZYC 3  
 FS STEREOSEARCH  
 MF C28 H36 O2  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, SYNTHLINE, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:987

REFERENCE 2: 138:101092

REFERENCE 3: 137:135223

REFERENCE 4: 136:369889

REFERENCE 5: 70:29167

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 13:00:46 ON 24 APR 2004  
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:00:46 ON 24 APR 2004  
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr tot 139

L39 ANSWER 1 OF 2 USPATFULL on STN

AN 2003:153499 USPATFULL  
 TI Treatment of ophthalmic diseases  
 IN Dykens, James Alan, Encinitas, CA, UNITED STATES  
 Gordon, Katherine, Winchester, MA, UNITED STATES  
 PI US 2003105167 A1 20030605  
 AI US 2002-313172 A1 20021205 (10)  
 PRAI US 2001-336599P 20011205 (60)  
 DT Utility  
 FS APPLICATION  
 LREP BROMBERG & SUNSTEIN LLP, 125 SUMMER STREET, BOSTON, MA, 02110-1618  
 CLMN Number of Claims: 19  
 ECL Exemplary Claim: 1  
 DRWN 2 Drawing Page(s)  
 LN.CNT 975


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of using protective compounds for the prevention or treatment of ophthalmic diseases, disorders or injuries in a subject. The method comprises the step of administering a predetermined polycyclic phenolic compound to a subject in need thereof. The polycyclic phenolic compound is selected from those having at least one terminal phenolic group and at least one other cyclic group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 21003-01-0  
 (in protection of trabecular meshwork cells from glutamate toxicity;  
 polycyclic phenolic compds. for treatment of ophthalmic diseases)  
 RN 21003-01-0 USPATFULL  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(tricyclo[3.3.1.13,7]dec-1-yl)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 535921-41-6  
 (polycyclic phenolic compds. for treatment of ophthalmic diseases)  
 RN 535921-41-6 USPATFULL  
 CN Estra-1,3,5(10)-trien-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
 (9β,14β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L39 ANSWER 2 OF 2 USPATFULL on STN  
 AN 2002:192107 USPATFULL  
 TI Modified, hydroxy-substituted aromatic structures having cytoprotective activity  
 IN Covey, Douglas F., Ballwin, MO, UNITED STATES  
 PA Washington University (U.S. corporation)  
 PI US 2002103178 A1 20020801  
 AI US 2001-7450 A1 20011105 (10)  
 PRAI US 2000-245791P 20001103 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE, 16TH FLOOR,  
 ST LOUIS, MO, 63102  
 CLMN Number of Claims: 51  
 ECL Exemplary Claim: 1  
 DRWN 7 Drawing Page(s)  
 LN.CNT 1504


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to modified, hydroxy-bearing aromatic ring structures having cytoprotective activity. More specifically, in a first embodiment the present invention is directed to phenolic compounds, and in particular steriods (e.g., estrogens), wherein a non-fused polycyclic, hydrophobic substituent is attached to the hydroxy-substituted A-ring thereof. The present invention is further directed to a process for conferring cytoprotection to a population of cells involving the administration of the compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 21003-01-0P, ZYC 3 422508-94-9P 422508-95-0P  
 422508-96-1P 422508-97-2P 422508-99-4P  
 422509-00-0P 422509-01-1P 422509-02-2P, ZYC  
 26 422566-94-7P, ZYC 33  
 (preparation of estrane derivs. having cytoprotective activity)  
 RN 21003-01-0 USPATFULL  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(tricyclo[3.3.1.13,7]dec-1-yl)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 422508-94-9 USPATFULL  
 CN Estra-1,3,5(10)-trien-3,17-diol, 4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8α,9β,13α,14β,17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-95-0 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8α,9β,13α,14β,17.α-lphα.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-96-1 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-97-2 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-99-4 USPATFULL

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-tricyclo[3.3.1.13,7]dec-1-yl-,  
(8α,9β,13α,14β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422509-00-0 USPATFULL

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8α,9β,13α,14β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422509-01-1 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol, 4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-,  
(17β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422509-02-2 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl-, (17β)- (9CI). (CA INDEX NAME)


Absolute stereochemistry.



RN 422566-94-7 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-, (8α,9β,13α,14β,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 422508-93-8P

(preparation of estrane derivs. having cytoprotective activity)

RN 422508-93-8 USPATFULL

CN Estra-1,3,5(10)-triene-3,17-one, 3-hydroxy-4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 13:01:07 ON 24 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Apr 2004 VOL 140 ISS 18  
FILE LAST UPDATED: 23 Apr 2004 (20040423/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 138

L38 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:435321 HCAPLUS  
DN 139:987  
ED Entered STN: 06 Jun 2003  
TI Treatment of ophthalmic diseases with polycyclic phenolic compounds  
IN Dykens, James Alan; Gordon, Katherine  
PA USA  
SO U.S. Pat. Appl. Publ., 13 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
IC ICM A61K031-05  
NCL 514732000  
CC 1-12 (Pharmacology)  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003105167	A1	20030605	US 2002-313172	20021205
WO 2003047559	A1	20030612	WO 2002-US39098	20021205

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-336599P P 20011205

AB The present invention relates to a method of using protective compds. for the prevention or treatment of ophthalmic diseases, disorders or injuries in a subject. The method comprises the step of administering a predetd. polycyclic phenolic compound to a subject in need thereof. The polycyclic phenolic compound is selected from those having at least one terminal phenolic group and at least one other cyclic group. Intraocular administration of 17 $\beta$ -estradiol and ent-17 $\beta$ -estradiol leads to survival of axotomized retinal ganglion cells in adult rats.

ST ophthalmic disease treatment polycyclic phenolic compd; estradiol protection retinal ganglion cell death

IT Biological transport  
 (axonal, retrograde, reducing cell death caused by decreased; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Phenols, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compds., polycyclic; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Receptors

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (dicarboxylate, cell death caused by overexcitation of; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Carboxylic acids, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (dicarboxylic, receptors, cell death caused by overexcitation of; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Neurotransmitters

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (excitatory, reducing cell death caused by exposure to; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Eye

(ganglion cell; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Pressure

(hydrostatic, reducing cell death caused by increased; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Apoptosis

Cell death  
 (in ophthalmic tissue, reduction of; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Eye, disease

(injury; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Pressure

(intraocular, normalization of; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Eye, disease

(optic neuropathy; polycyclic phenolic compds. for treatment of

ophthalmic diseases)

IT Eye  
 (pigment epithelium, protection from cell death; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Drug delivery systems  
 Eye, disease  
 Human  
 (polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Necrosis  
 Stress, animal  
 (reduction of cell death in ophthalmic tissue caused by; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Neurotrophic factors  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (reducing cell death caused by decreased support by; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Radical ions  
 (reducing cell death caused by exposure to; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Mitochondria  
 (stabilization of structure and function of; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT Eye  
 (trabecular meshwork, protection from glutamate toxicity; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT 50-28-2, 17 $\beta$ -Estradiol, biological studies 493001-44-8  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in protection of axotomized retinal ganglion cells; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT 104849-43-6 114549-37-0  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in protection of human retinal pigment epithelial cells from cell death; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT 21003-01-0 21003-02-1  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in protection of trabecular meshwork cells from glutamate toxicity; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT 57-91-0, 17 $\alpha$ -Estradiol 535921-41-6  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT 14127-61-8, Calcium ion, biological studies  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (reducing cell death caused by acute loading of; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT 56-86-0, L-Glutamic acid, biological studies 89-00-9,  
 2,3-Pyridinedicarboxylic acid 2552-55-8 67145-93-1, Kainite  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (reducing cell death caused by exposure to; polycyclic phenolic compds. for treatment of ophthalmic diseases)

IT 125978-95-2, Nitric oxide synthase  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (reducing cell death caused by overexpression of; polycyclic phenolic compds. for treatment of ophthalmic diseases)


IT 21003-01-0

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in protection of trabecular meshwork cells from glutamate toxicity;  
 polycyclic phenolic compds. for treatment of ophthalmic diseases)

RN 21003-01-0 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(tricyclo[3.3.1.13,7]dec-1-yl)-  
 (9CI). (CA INDEX NAME)

Absolute stereochemistry.




IT 535921-41-6

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polycyclic phenolic compds. for treatment of ophthalmic diseases)

RN 535921-41-6 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
 (9β,14β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L38 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:732495 HCAPLUS

DN 138:101092

ED Entered STN: 27 Sep 2002

TI Neuroprotective effects of a novel non-receptor-binding estrogen analogue

AU Liu, Ran; Yang, Shao-Hua; Perez, Evelyn; Yi, Kun Don; Wu, Samuel S.;  
 Eberst, Kathleen; Prokai, Laszlo; Prokai-Tatrai, Katalin; Cai, Zu Yun;  
 Covey, Douglas F.; Day, Arthur L.; Simpkins, James W.

CS Health Science Center at Fort Worth, Department of Pharmacology and  
 Neuroscience, University of North Texas, USA

SO Stroke (2002), 33(10), 2485-2491

CODEN: SJCCA7; ISSN: 0039-2499

PB Lippincott Williams & Wilkins

DT Journal

LA English

CC 2-4 (Mammalian Hormones)

AB Although estrogens are neuroprotective, hormonal effects limit their clin.  
 application. Estrogen analogs with neuroprotective function but lacking

hormonal properties would be more attractive. The present study was undertaken to determine the neuroprotective effects of a novel 2-adamantyl estrogen analog, ZYC3. Cytotoxicity was induced in HT-22 cells by 10 mmol/L glutamate. 17 $\beta$ -Estradiol (E2) or ZYC3 was added immediately before the exposure to glutamate. Cell viability was determined by calcein assay. The binding of E2 and ZYC3 to human  $\alpha$  (ER $\alpha$ ) and  $\beta$  (ER $\beta$ ) estrogen receptors was determined by ligand competition binding assay. Ischemia/reperfusion injury was induced by temporary middle cerebral artery occlusion (MCAO). E2 or ZYC3 (100/ $\mu$ g/kg) was administered 2 h or immediately before MCAO, resp. Infarct volume was determined

by 2,3,5-triphenyltetrazolium chloride staining. Cerebral blood flow was recorded during and within 30 min after MCAO by a hydrogen clearance method. ZYC3 significantly decreased toxicity of glutamate with a potency 10-fold that of E2. ZYC3 did not bind to either ER $\alpha$  or ER $\beta$ . Infarct volume was significantly reduced to 122.4 and 83.1 mm<sup>3</sup> in E2 and ZYC3 groups, resp., compared with 252.6 mm<sup>3</sup> in the ovariectomized group. During MCAO, both E2 and ZYC3 significantly increased cerebral blood flow in the nonischemic side, while no significant differences were found in the ischemic side. However, E2 and ZYC3 significantly increased cerebral blood flow in both sides within 30 min after reperfusion. The study shows that ZYC3, a non-receptor-binding estrogen analog, possesses both neuroprotective and vasoactive effects, which offers the possibility of clin. application for stroke without the side effects of estrogens. It also suggests that both the neuroprotective and vasoactive effects of estrogen are receptor independent.

ST neuroprotection vasodilation adamantyl estrogen analog receptor binding stroke; ZYC3 neuroprotection vasodilation receptor binding stroke

IT Circulation

(cerebral; neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog in stroke model)

IT Reperfusion

(injury; neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog in stroke model)

IT Brain, disease

(ischemia; neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog in stroke model)

IT Human

Vasodilators

(neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog in stroke model)

IT Cytoprotective agents

(neuroprotective; neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog in stroke model)

IT Brain, disease

(stroke; neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog in stroke model)

IT Estrogen receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ ; neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog in stroke model)

IT Estrogen receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ ; neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog in stroke model)

IT 50-28-2, 17 $\beta$ -Estradiol, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(neuroprotective and vasoactive effects of non-receptor-binding adamantyl estrogen analog and estradiol in stroke model)

IT 21003-01-0, ZYC 3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neuroprotective and vasoactive effects of non-receptor-binding  
adamantyl estrogen analog in stroke model)

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Behl, C; J Neurocytol 2000, V29, P351 HCAPLUS
- (2) Behl, C; Mol Pharmacol 1997, V51, P535 HCAPLUS
- (3) Couse, J; Endocr Rev 1999, V20, P358 HCAPLUS
- (4) Dubal, D; Endocrinology 2001, V142, P43 HCAPLUS
- (5) Dubal, D; Proc Natl Acad Sci 2001, V98, P1952 HCAPLUS
- (6) Dubey, R; Hypertension 2001, V37, P640 HCAPLUS
- (7) Garcia-Segura, L; Prog Neurobiol 2001, V63, P29 HCAPLUS
- (8) Ghose, A; J Chem Inf Comput Sci 1987, V27, P21 HCAPLUS
- (9) Grady, D; Ann Intern Med 2000, V132, P689 HCAPLUS
- (10) Green, P; Endocrinology 2001, V142, P400 HCAPLUS
- (11) Green, P; Int J Dev Neurosci 2000, V18, P347 HCAPLUS
- (12) Green, P; J Neurosci 1997, V17, P511 HCAPLUS
- (13) Green, P; J Steroid Biochem Mol Biol 1997, V63, P229 HCAPLUS
- (14) Green, P; Neuroscience 1998, V84, P7 HCAPLUS
- (15) Honda, K; J Neurosci Res 2000, V60, P321 HCAPLUS
- (16) Hurn, P; J Cereb Blood Flow Metab 1995, V15, P666 HCAPLUS
- (17) Hurn, P; J Cereb Blood Flow Metab 2000, V20, P631 HCAPLUS
- (18) Karas, R; Chest 1998, V114, P1508 MEDLINE
- (19) Katzenellenbogen, J; Environ Health Perspect 1995, V103(suppl 7), P99
- (20) Landers, J; Crit Rev Eukaryot Gene Expr 1992, V2, P19 HCAPLUS
- (21) Littell, R; J Anim Sci 1998, V76, P1216 HCAPLUS
- (22) Lunn, W; Tetrahedron 1968, V24, P6773 HCAPLUS
- (23) Maher, P; J Neurosci 1996, V16, P6394 HCAPLUS
- (24) Mant, J; Br J Obstet Gynaecol 1998, V105, P890 MEDLINE
- (25) Manthey, D; Eur J Biochem 2001, V268, P4285 HCAPLUS
- (26) McCullough, D; Physiologist 2001, V44, P269
- (27) McCullough, L; Stroke 2001, V32, P796 HCAPLUS
- (28) Moosmann, B; Proc Natl Acad Sci 1999, V96, P8867 HCAPLUS
- (29) Nikov, G; J Endocrinol 2001, V170, P137 HCAPLUS
- (30) Regan, R; Brain Res 1997, V764, P133 HCAPLUS
- (31) Rupprecht, R; Trends Neurosci 1999, V22, P410 HCAPLUS
- (32) SAS Institute; SAS STAT Software: Changes and Enhancements for Release  
6.12 1996
- (33) Sampei, K; Stroke 2000, V31, P738 HCAPLUS
- (34) Sawada, H; J Neurosci Res 1998, V54, P707 HCAPLUS
- (35) Simon, J; Circulation 2001, V103, P638 HCAPLUS
- (36) Simpkins, J; J Neurosurg 1997, V87, P724 HCAPLUS
- (37) Singh, M; J Neurosci 1999, V19, P1179 HCAPLUS
- (38) Stegmayr, B; Stroke 1997, V28, P1367 MEDLINE
- (39) Tan, S; J Neurochem 1998, V71, P95 HCAPLUS
- (40) Thorvaldsen, P; Stroke 1995, V26, P361 MEDLINE
- (41) Toung, T; Stroke 1998, V29, P1666 HCAPLUS
- (42) Viscoli, C; N Engl J Med 2001, V345, P1243 HCAPLUS
- (43) Watanabe, Y; Am J Physiol 2001, V281, PH155 HCAPLUS
- (44) Weaver, C; Brain Res 1997, V761, P338 HCAPLUS
- (45) Yang, S; J Appl Physiol 2002, V92, P195 HCAPLUS
- (46) Yang, S; J Cereb Blood Flow Metab 2001, V21, P174 HCAPLUS
- (47) Yang, S; Stroke 2000, V31, P745 HCAPLUS
- (48) Zhang, L; Neuroreport 2001, V12, P1919 HCAPLUS

IT 21003-01-0, ZYC 3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(neuroprotective and vasoactive effects of non-receptor-binding  
adamantyl estrogen analog in stroke model)

RN 21003-01-0 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(tricyclo[3.3.1.1.3,7]dec-1-yl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L38 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:353467 HCAPLUS  
 DN 136:369889  
 ED Entered STN: 12 May 2002  
 TI Preparation of estrane derivatives having cytoprotective activity  
 IN Covey, Douglas F.  
 PA Washington University, USA  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07J001-00  
 ICS A61P039-00; A61K031-565  
 CC 32-3 (Steroids)  
 Section cross-reference(s): 1, 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036605	A2	20020510	WO 2001-US46924	20011105 <--
	WO 2002036605	A3	20020711		
	WO 2002036605	C2	20021017		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002032509	A5	20020515	AU 2002-32509	20011105 <--
	US 2002103178	A1	20020801	US 2001-7450	20011105 <--
	EP 1330467	A2	20030730	EP 2001-992033	20011105 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-245791P	P	20001103		<--
	WO 2001-US46924	W	20011105		<--
OS	MARPAT	136:369889			
GI					



AB Estrane derivs., such as I [R1, R2 = non-fused, polycyclic hydrophobic substituent, H, (un)substituted alkyl; R3 = H, OH, oxo, (un)substituted alkyl], were prepared for their use as cytoprotective agents. Thus, estrane derivative II was prepared via reaction of 3-hydroxy-4-methylestra-1,3,5(10)-trien-17-one and 1-adamantananol. II showed ED<sub>50</sub> = 0.018 μM vs. neurons killed by 10 mM glutamate. The present invention was further directed to a process for conferring cytoprotection to a population of cells involving the administration of the compound

ST estrane deriv prepn cytoprotective neuroprotective

IT Cytoprotective agents  
 (neuroprotective; preparation of estrane derivs. having cytoprotective activity)

IT Human  
 (preparation of estrane derivs. having cytoprotective activity)

IT Estrogens  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of estrane derivs. having cytoprotective activity)

IT 3736-22-9, ENT-17β-Estradiol  
 RL: PAC (Pharmacological activity); BIOL (Biological study)  
 (preparation of estrane derivs. having cytoprotective activity)

IT 53-16-7, Estrone, reactions 57-91-0, 17α-Estradiol  
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
 (preparation of estrane derivs. having cytoprotective activity)

IT 2259-89-4P 2626-12-2P, ZYC 24 21003-01-0P, ZYC 3  
 21003-02-1P, ZYC 14 52619-51-9P, ZYC 21 177353-06-9P, ZYC 17  
 177353-07-0P, ZYC 15 422508-94-9P 422508-95-0P  
 422508-96-1P 422508-97-2P 422508-98-3P  
 422508-99-4P 422509-00-0P 422509-01-1P  
 422509-02-2P, ZYC 26 422566-88-9P, ZYC 20 422566-89-0P, ZYC 25  
 422566-91-4P, ZYC 18 422566-93-6P, ZYC 16 422566-94-7P, ZYC 33  
 422567-08-6P, ZYC 34  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of estrane derivs. having cytoprotective activity)

IT 50-28-2, 17β-Estradiol, biological studies  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of estrane derivs. having cytoprotective activity)

IT 75-65-0, tert-Butanol, reactions 768-95-6, Tricyclo[3.3.1.13,7]decan-1-ol 68969-90-4 98543-85-2  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of estrane derivs. having cytoprotective activity)

IT 422508-93-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of estrane derivs. having cytoprotective activity)

IT 21003-01-0P, ZYC 3 422508-94-9P 422508-95-0P  
 422508-96-1P 422508-97-2P 422508-99-4P  
 422509-00-0P 422509-01-1P 422509-02-2P, ZYC 26  
 422566-94-7P, ZYC 33


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of estrane derivs. having cytoprotective activity)

RN 21003-01-0 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(tricyclo[3.3.1.13,7]dec-1-yl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-94-9 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-,  
(8α,9β,13α,14β,17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-95-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8α,9β,13α,14β,17.alp ha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-96-1 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
(17 $\alpha$ ) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-97-2 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-  
tricyclo[3.3.1.13,7]dec-1-yl-, (17 $\alpha$ ) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422508-99-4 HCPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-tricyclo[3.3.1.13,7]dec-1-yl-,  
(8 $\alpha$ ,9 $\beta$ ,13 $\alpha$ ,14 $\beta$ ) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422509-00-0 HCPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8 $\alpha$ ,9 $\beta$ ,13 $\alpha$ ,14 $\beta$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422509-01-1 HCPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 4-methyl-2-tricyclo[3.3.1.13,7]dec-1-yl-, (17 $\beta$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422509-02-2 HCPLUS


CN Estra-1,3,5(10)-triene-3,17-diol, 4-(1-methylpropyl)-2-tricyclo[3.3.1.13,7]dec-1-yl-, (17 $\beta$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422566-94-7 HCAPLUS  
 CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
 (8α,9β,13α,14β,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 422508-93-BP  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of estrane derivs. having cytoprotective activity)  
 RN 422508-93-8 HCAPLUS  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-4-(1-methylpropyl)-2-  
 tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ED Entered STN: 11 Apr 2002  
 TI The estrogen receptor is not essential for all estrogen neuroprotection:  
 new evidence from a new analog  
 AU Xia, Shuli; Cai, Zu Yun; Thio, Liu Lin; Kim-Han, Jeong Sook; Dugan, Laura  
 L.; Covey, Douglas F.; Rothman, Steven M.  
 CS Department of Neurology, Washington University School of Medicine, St.  
 Louis, MO, 63110, USA  
 SO Neurobiology of Disease (2002), 9(3), 282-293  
 CODEN: NUDIEM; ISSN: 0969-9961  
 PB Elsevier Science  
 DT Journal  
 LA English  
 CC 2-4 (Mammalian Hormones)  
 Section cross-reference(s): 32  
 AB We synthesized an estrogen analog, ZYC-5, lacking activity at the classical estrogen receptor and examined its neuroprotective potential against necrosis induced by N-methyl-d-aspartate (NMDA) and apoptosis/necrosis induced by the NMDA receptor antagonist (+)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid (CPP). ZYC-5 protected cortical neurons in a dose-dependent manner, and the neuroprotection was more robust than with 17 $\beta$ -estradiol. The effect of ZYC-5 was not mediated by the classical estrogen receptor, because it was unaffected by the antagonists 4-hydroxytamoxifen and ICI 182,780. The ZYC-5 protection against excitotoxicity was not directly mediated through the NMDA receptor, because there was no effect of ZYC-5 on NMDA current or the intracellular calcium increase induced by NMDA. Results obtained with the free-radical-sensitive dye, dihydroethidium, suggested that the neuroprotection of ZYC-5 was partly related to its radical scavenging properties. Although some of estrogen's neuroprotective effects may depend upon the estrogen receptor, our results suggest the possibility of neuroprotection without hormonal side effects.  
 ST estrogen analog ZYC5 prepn neuroprotection  
 IT Glutamate receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (NMDA-binding; preparation of estrogen analog (ZYC-5) that shows neuroprotection not mediated by estrogen receptors or NMDA receptors)  
 IT Brain  
 (cortex; preparation of estrogen analog (ZYC-5) that shows neuroprotection not mediated by estrogen receptors or NMDA receptors)  
 IT Nerve, disease  
 Nerve, disease  
 (death; preparation of estrogen analog (ZYC-5) that shows neuroprotection not mediated by estrogen receptors or NMDA receptors)  
 IT Cell death  
 Cell death  
 (neuron; preparation of estrogen analog (ZYC-5) that shows neuroprotection not mediated by estrogen receptors or NMDA receptors)  
 IT Cytoprotective agents  
 (neuroprotective; preparation of estrogen analog (ZYC-5) that shows neuroprotection not mediated by estrogen receptors or NMDA receptors)  
 IT Radical scavengers  
 (preparation of estrogen analog (ZYC-5) that shows neuroprotection in relation to its radical scavenging properties)  
 IT Estrogen receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of estrogen analog (ZYC-5) that shows neuroprotection not mediated by estrogen receptors or NMDA receptors)  
 IT 444571-93-1P, ZYC 5  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of estrogen analog (ZYC-5) that shows neuroprotection not mediated by estrogen receptors or NMDA receptors)

IT 21003-01-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of estrogen analog (ZYC-5) that shows neuroprotection not  
 mediated by estrogen receptors or NMDA receptors)

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Gridley, K; Mol Pharmacol 1998, V54, P874 HCPLUS
- (2) Grynkiewicz, G; J Biol Chem 1985, V260, P3440 HCPLUS
- (3) Gwag, B; Neuroscience 1997, V77, P393 HCPLUS
- (4) Harms, C; J Neurosci 2001, V21, P2600 HCPLUS
- (5) Henderson, V; Am J Med 1997, V103, P11S HCPLUS
- (6) Hurn, P; J Cereb Blood Flow Metab 2000, V20, P631 HCPLUS
- (7) Hwang, J; Exp Neurol 1999, V159, P124 HCPLUS
- (8) Ikonomidou, C; Science 1999, V283, P70 HCPLUS
- (9) Joza, N; Nature 2001, V410, P549 HCPLUS
- (10) Keller, J; J Neurosci Res 1997, V50, P522 HCPLUS
- (11) Lunn, W; Tetrahedron 1968, V24, P6773 HCPLUS
- (12) Mayeux, R; Am J Epidemiol 1995, V142, P820 MEDLINE
- (13) McDonald, J; Brain Res 1997, V759, P228 HCPLUS
- (14) Miller, C; Steroids 1996, V61, P305 HCPLUS
- (15) Mooradian, A; J Steroid Biochem Mol Biol 1993, V45, P509 HCPLUS
- (16) Moosmann, B; Proc Natl Acad Sci USA 1999, V96, P8867 HCPLUS
- (17) Pike, C; J Neurochem 1999, V72, P1552 HCPLUS
- (18) Purdie, D; Br J Cancer 1999, V81, P559 MEDLINE
- (19) Regan, R; Brain Res 1997, V764, P133 HCPLUS
- (20) Reynolds, I; J Neurosci 1995, V15, P1318 HCPLUS
- (21) Rifici, V; Metabolism 1992, V41, P1110 MEDLINE
- (22) Rose, K; Methods in Toxicity 1992, P46
- (23) Sawada, H; J Neurosci Res 1998, V54, P707 HCPLUS
- (24) Shughrue, P; Front Neuroendocrinol 2000, V21, P95 HCPLUS
- (25) Singer, C; J Neurosci 1999, V19, P2455 HCPLUS
- (26) Singer, C; Neuroreport 1998, V9, P2565 HCPLUS
- (27) Singer, C; Neurosci Lett 1996, V212, P13 HCPLUS
- (28) Singh, M; J Neurosci 1999, V19, P1179 HCPLUS
- (29) Tang, M; Lancet 1996, V348, P429 HCPLUS
- (30) Terro, F; Neurosci Lett 2000, V278, P149 HCPLUS
- (31) Vegeto, E; J Neurosci 2001, V21, P1809 HCPLUS
- (32) Watters, J; J Neurosci 1998, V18, P6672 HCPLUS
- (33) Weaver, C; Brain Res 1997, V761, P338 HCPLUS
- (34) Yamada, K; Br J Pharmacol 1996, V117, P1663 HCPLUS

IT 444571-93-1P, ZYC 5


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of estrogen analog (ZYC-5) that shows neuroprotection not  
 mediated by estrogen receptors or NMDA receptors)

RN 444571-93-1 HCPLUS


CN Estra-1,3,5(10)-triene-3,17-diol, 2-tricyclo[3.3.1.13,7]dec-1-yl-,  
 (17 $\beta$ ) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 21003-01-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of estrogen analog (ZYC-5) that shows neuroprotection not  
 mediated by estrogen receptors or NMDA receptors)  
 RN 21003-01-0 HCPLUS  
 CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(tricyclo[3.3.1.13,7]dec-1-yl)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L38 ANSWER 5 OF 5 HCPLUS COPYRIGHT 2004 ACS on STN  
 AN 1969:29167 HCPLUS  
 DN 70:29167  
 ED Entered STN: 12 May 1984  
 TI Adamantyl carbonium ion as a dehydrogenating agent; its reactions with  
 estrone  
 AU Lunn, W. H. W.; Farkas, Eugene  
 CS Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, USA  
 SO Tetrahedron (1968), 24(23), 6773-6  
 CODEN: TETRAB; ISSN: 0040-4020  
 DT Journal  
 LA English  
 CC 32 (Steroids)  
 OS CASREACT 70:29167  
 GI For diagram(s), see printed CA Issue.  
 AB An unusual and useful dehydrogenation of estrone to  $\Delta^9(11)$ -estrone  
 (I) occurred on its reaction with the adamantyl carbonium ion. With  
 modified conditions both tert-Bu and adamantyl carbonium ion sources gave  
 2-substituted estrone derivs. in this reaction.  
 ST adamantyl carbonium ion estrone; carbonium ion adamantyl estrone; estrone  
 dehydrogenation; dehydrogenation estrone  
 IT Dehydrogenation catalysts  
 (adamantyl carbonium ions as, for estrone)  
 IT 19-Norsteroids  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (dehydrogenation of)  
 IT Carbonium compounds  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (in dehydrogenation of estrone)  
 IT 21003-01-0P 21003-02-1P 21003-03-2P 21003-04-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 IT 53-16-7, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (with adamantyl carbonium ions)  
 IT 21003-01-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 21003-01-0 HCPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(tricyclo[3.3.1.13,7]dec-1-yl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>